MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

CytomX Therapeutics Company Profile (NASDAQ:CTMX)

Consensus Ratings for CytomX Therapeutics (NASDAQ:CTMX) (?)
Ratings Breakdown: 4 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $20.33 (106.85% upside)

Analysts' Ratings History for CytomX Therapeutics (NASDAQ:CTMX)
Show:
DateFirmActionRatingPrice TargetActions
5/10/2016OppenheimerReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/16/2016Jefferies GroupReiterated RatingBuy$19.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/20/2016Cowen and CompanyReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/2/2015Bank of AmericaInitiated CoverageBuy$20.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/26/2014 forward)
Earnings History for CytomX Therapeutics (NASDAQ:CTMX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
5/6/2016        
5/6/2016($0.26)($0.44)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for CytomX Therapeutics (NASDAQ:CTMX)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20163($0.34)($0.11)($0.25)
Q2 20162($0.44)($0.32)($0.38)
Q3 20162($0.45)($0.33)($0.39)
Q4 20162($0.47)($0.35)($0.41)
(Data provided by Zacks Investment Research)
Dividend History for CytomX Therapeutics (NASDAQ:CTMX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for CytomX Therapeutics (NASDAQ:CTMX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
6/10/2016Timothy M ShannonDirectorSell48,427$10.07$487,659.89View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/7/2016Ix L.P. CanaanDirectorSell111,498$10.01$1,116,094.98View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/3/2016Ix L.P. CanaanDirectorSell59,621$10.80$643,906.80View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/1/2016Ix L.P. CanaanDirectorSell22,463$10.75$241,477.25View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/27/2016Ix L.P. CanaanDirectorSell25,082$10.60$265,869.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/26/2016Timothy M ShannonDirectorSell51,343$10.34$530,886.62View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/24/2016Ix L.P. CanaanDirectorSell13,253$10.09$133,722.77View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/20/2016Ix L.P. CanaanDirectorSell8,687$10.10$87,738.70View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/14/2015Cynthia J LaddVPBuy3,000$12.00$36,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/14/2015Frederick W GluckDirectorBuy15,000$12.00$180,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/14/2015James E FlynnInsiderBuy625,000$12.00$7,500,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for CytomX Therapeutics (NASDAQ:CTMX)
DateHeadline
06/13/16 03:06 PMCYTOMX THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a V -
06/13/16 07:19 AMCytomX Therapeutics Appoints John A. Scarlett, M.D., to Board of Directors - [at noodls] - SOUTH SAN FRANCISCO, Calif., June 13, 2016 (GLOBE NEWSWIRE) -- CytomX Therapeutics (Nasdaq:CTMX), a biopharmaceutical company developing investigational Probody™ therapeutics for the treatment of cancer, ...
06/01/16 11:30 AMCytomX Therapeutics, Inc. :CTMX-US: Earnings Analysis: Q1, 2016 By the Numbers : June 1, 2016 -
05/27/16 01:39 PMAre Analysts Bearish CytomX Therapeutics Inc (NASDAQ:CTMX) After Last Week? - Wall Street Hints and News - Are Analysts Bearish CytomX Therapeutics Inc (NASDAQ:CTMX) After Last Week?Wall Street Hints and NewsOut of 3 analysts covering CytomX Therapeutics (NASDAQ:CTMX), 4 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. CytomX Therapeutics has been the topic of 3 analyst reports since November 2, 2015 according to StockzIntelligence ...Does CytomX Therapeutics Inc Have Any Gas After Today's Huge Increase?The Postall 5 news articles »
05/26/16 12:43 PMEarnings Review and Stock Rundown for CytomX Therapeutics Inc (NASDAQ:CTMX) - Wall Street Hints and News - Earnings Review and Stock Rundown for CytomX Therapeutics Inc (NASDAQ:CTMX)Wall Street Hints and NewsInvestors and analysts will be paying close attention when the company posts earnings results. Earnings numbers can provide insight into a company's overall profitability. Covering equity analysts are expecting CytomX Therapeutics Inc (NASDAQ:CTMX) to ...and more »
05/26/16 12:43 PMCytomX Therapeutics : to Present at the Jefferies 2016 Healthcare Conference - (GlobeNewswire) - CytomX Therapeutics, Inc. (Nasdaq:CTMX), a biopharmaceutical company developing investigational Probody therapeutics for the treatment of cancer, will present at the Jefferies 2016 Healthcare Conference in New York, NY. Bob Goeltz ...
05/24/16 07:16 AMCytomX to Present at the Jefferies 2016 Healthcare Conference - [at noodls] - SOUTH SAN FRANCISCO, Calif., May 24, 2016 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a biopharmaceutical company developing investigational Probody™ therapeutics for the treatment of ...
05/18/16 10:56 AMCytomX Therapeutics, Inc. (CTMX) Investment Down in Latest Report from Deerfield Management Co - Finance Daily - CytomX Therapeutics, Inc. (CTMX) Investment Down in Latest Report from Deerfield Management CoFinance DailyDeerfield Management Co decreased its stake in CytomX Therapeutics, Inc. stock by 0.3% in the quarter ending 03/31/2016. Its investment was worth $12,170,000 a decrease of $7,573,000 as of quarter end. Here are a few additional firms who have ...
05/18/16 10:56 AMRevenue Update on CytomX Therapeutics Inc(NASDAQ:CTMX) - Trade Calls - Revenue Update on CytomX Therapeutics Inc(NASDAQ:CTMX)Trade CallsCytomX Therapeutics Inc(NASDAQ:CTMX) announced the earnings results for Fiscal Year 2016 and Q1. The results came in during Pre-market on May 6, 2016. Company reported revenue of $2.22M. Analysts estimated a revenue of $4.09M. Earnings per ...
05/16/16 10:46 AMCytomX Therapeutics, Inc. (NASDAQ:CTMX) Broker Price Targets For The Coming Week - Share Trading News - CytomX Therapeutics, Inc. (NASDAQ:CTMX) Broker Price Targets For The Coming WeekShare Trading NewsMarket analysts have recently updated their ratings and price targets on shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX). The latest reports which are currently in issue on Sunday 15th of May state 0 analysts have a rating of “strong buy”, 0 analysts ...and more »
05/14/16 10:41 AMCytomx Therapeutics Incorporated (NASDAQ:CTMX) Shorts Decreased by 3.24% After Short Covering - Wall Street Hints and News - Cytomx Therapeutics Incorporated (NASDAQ:CTMX) Shorts Decreased by 3.24% After Short CoveringWall Street Hints and NewsThe short interest to Cytomx Therapeutics Incorporated's float is 4.53%. The stock decreased 1.09% or $0.11 on May 13, hitting $10. About 69,946 shares traded hands or 11.88% up from the average. CytomX Therapeutics Inc (NASDAQ:CTMX) has declined ...and more »
05/13/16 12:04 PMCYTOMX THERAPEUTICS, INC. Financials -
05/13/16 10:35 AMCytomX Therapeutics is Now Oversold (CTMX) - A stock is considered to be oversold if the RSI reading falls below 30. In trading on Thursday, shares of CytomX Therapeutics Inc (CTMX) entered into oversold territory, hitting an RSI reading of 27.0, after changing hands as low as $10.765 per share.
05/11/16 10:41 AMConsensus Rating Review for CytomX Therapeutics Inc (NASDAQ:CTMX) - B.O.D.Y Confidential - Consensus Rating Review for CytomX Therapeutics Inc (NASDAQ:CTMX)B.O.D.Y ConfidentialEquity research analysts currently have a consensus rating of 1 on shares of CytomX Therapeutics Inc (NASDAQ:CTMX). Sell-side analysts will typically rate a company's stock based on extensive research. These ratings usually translate into a Buy, Sell, ...and more »
05/07/16 10:24 AMCytomX Therapeutics reports 1Q loss - Yahoo Finance UK - CytomX Therapeutics reports 1Q lossYahoo Finance UKSOUTH SAN FRANCISCO, Calif. (AP) _ CytomX Therapeutics Inc. (CTMX) on Friday reported a loss of $16 million in its first quarter. On a per-share basis, the South San Francisco, California-based company said it had a loss of 44 cents. The results missed ...and more »
05/07/16 10:24 AMEarnings Outlook on CytomX Therapeutics Inc (NASDAQ:CTMX) - B.O.D.Y Confidential - Earnings Outlook on CytomX Therapeutics Inc (NASDAQ:CTMX)B.O.D.Y ConfidentialAnalysts and investors will be anticipating CytomX Therapeutics Inc (NASDAQ:CTMX)'s next earnings release which is expected to be posted on or around 2016-06-06. Sell-side research firms on Wall Street are expecting that the company will post EPS of ...and more »
05/06/16 06:14 AMCytomX Announces First Quarter 2016 Financial Results - [at noodls] - SOUTH SAN FRANCISCO, Calif., May 06, 2016 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a biopharmaceutical company developing investigational Probody™ therapeutics for the treatment of ...
05/06/16 06:10 AMCytomX Therapeutics reports 1Q loss -
05/06/16 06:03 AMCYTOMX THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and -
05/06/16 06:03 AMCYTOMX THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report -
05/03/16 10:27 AMThis Weeks Broker Price Targets For CytomX Therapeutics, Inc. (NASDAQ:CTMX) - Share Trading News - This Weeks Broker Price Targets For CytomX Therapeutics, Inc. (NASDAQ:CTMX)Share Trading News11/02/2015 – Bank of America Merrill Lynch began new coverage on CytomX Therapeutics, Inc. giving the company a “buy” rating. They now have a USD 20 price target on the stock. 11/02/2015 – Jefferies began new coverage on CytomX Therapeutics, Inc.and more »
04/30/16 10:32 AMShare Performance and Target Price Review CytomX Therapeutics Inc (NASDAQ:CTMX) - B.O.D.Y Confidential - Share Performance and Target Price Review CytomX Therapeutics Inc (NASDAQ:CTMX)B.O.D.Y ConfidentialDuring the most recent trading session, shares of CytomX Therapeutics Inc (NASDAQ:CTMX) ended up with a move of +0.86%. Sell-side analysts have given a consensus target price of $21.67 on company shares. Target price projections may differ greatly ...and more »
04/28/16 03:10 PMCYTOMX THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers -
04/28/16 12:11 PMETF’s with exposure to CytomX Therapeutics, Inc. : April 28, 2016 -
04/27/16 10:58 AMCytomX Therapeutics, Inc. (NASDAQ:CTMX) Latest Broker Views - Risers & Fallers - CytomX Therapeutics, Inc. (NASDAQ:CTMX) Latest Broker ViewsRisers & FallersA number of investment brokers have recently updated their price targets on shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX). According to the latest broker reports outstanding on Tuesday 26th of April, 0 analysts have a rating of “strong buy”, 0 ...Cytomx Therapeutics Incorporated (NASDAQ:CTMX) Shorts Decreased by 3.22% After Short CoveringCCH Daily NewsCytomX to Present at the 2016 Bank of America Merrill Lynch Healthcare ConferenceNasdaqall 3 news articles »
04/27/16 07:27 AMCytomX Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : CTMX-US : April 27, 2016 -
04/26/16 11:00 AMCytomx Therapeutics Incorporated (NASDAQ:CTMX) Shorts Decreased by 3.22% After Short Covering - CCH Daily News - Cytomx Therapeutics Incorporated (NASDAQ:CTMX) Shorts Decreased by 3.22% After Short CoveringCCH Daily NewsCytomX Therapeutics Inc (NASDAQ:CTMX) has risen 6.00% since March 27, 2016 and is uptrending. It has outperformed by 0.91% the S&P500. CytomX Therapeutics, Inc. is a United States biotechnology company. The company has a market cap of $495.00 ...and more »
04/26/16 11:00 AMCytomX Therapeutics Inc (NASDAQ:CTMX) Share Rating Recap - B.O.D.Y Confidential - CytomX Therapeutics Inc (NASDAQ:CTMX) Share Rating RecapB.O.D.Y ConfidentialShares of CytomX Therapeutics Inc (NASDAQ:CTMX) are tracked by analysts as well as crowd investors. Research from Beta Systems keeps track of crowd sourced sentiment and provides consensus stock ratings. The rating information comes mainly from ...
04/26/16 07:38 AMCytomX to Present at the 2016 Bank of America Merrill Lynch Healthcare Conference - [at noodls] - SOUTH SAN FRANCISCO, Calif., April 26, 2016 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a biopharmaceutical company developing investigational Probody™ therapeutics for the treatment of ...
04/22/16 11:04 AMCytomX Therapeutics, Inc. (NASDAQ:CTMX) Updated Broker Ratings - Risers & Fallers - FierceBiotechCytomX Therapeutics, Inc. (NASDAQ:CTMX) Updated Broker RatingsRisers & FallersA number of investment brokers have recently updated their price targets on shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX). According to the latest broker reports outstanding on Friday 22nd of April, 0 analysts have a rating of “strong buy”, 0 ...CytomX (CTMX), AbbVie (ABBV) Enter Collaboration to Develop Probody Drug Conjugates Against CD71StreetInsider.comStocks within Analysts Screening: AbbVie Inc. (NYSE:ABBV) , TherapeuticsMD, Inc. (NYSEMKT:TXMD)Street UpdatesAbbVie teams up with CytomX in Probody Drug ConjugatesSeeking AlphaJutia Group (press release) (blog) -Hot Stocks Point -Seneca Globeall 11 news articles »
04/22/16 11:04 AMCompany Update (NYSE:ABBV): AbbVie and CytomX Announce Strategic Collaboration for Probody Drug Conjugates - [PR Newswire] – NORTH CHICAGO, Ill. and SOUTH SAN FRANCISCO, Calif., April 21, 2016 /PRNewswire/ — AbbVie (ABBV) and CytomX Therapeutics, Inc. (CTMX) today announced that they have entered into a collaboration to co-develop and co-commercialize Probody ...
04/21/16 04:00 PMCytomX AbbVie Probody Drug Conjugates Collaboration Call scheduled for 5:00 pm ET today -
04/21/16 03:21 PMCytomX and AbbVie Announce Strategic Collaboration for Probody Drug Conjugates - [at noodls] - - Companies to Jointly Develop and Commercialize Probody Drug Conjugates Directed Against CD71 - AbbVie to Receive the Right to License Probody Drug Conjugates for up to Two Additional Undisclosed Targets ...
04/21/16 03:13 PMCYTOMX THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Regulation FD Disclosure, F -
04/21/16 03:01 PMAbbVie and CytomX Announce Strategic Collaboration for Probody Drug Conjugates - [PR Newswire] - NORTH CHICAGO, Ill. and SOUTH SAN FRANCISCO, Calif., April 21, 2016 /PRNewswire/ -- AbbVie (ABBV) and CytomX Therapeutics, Inc. (CTMX) today announced that they have entered into a collaboration to co-develop and co-commercialize Probody™ Drug Conjugates against CD71, also known as transferrin receptor 1 (TfR1). Probody therapeutics are designed to take advantage of unique conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues. "We believe that the Probody platform provides a differentiated opportunity to combine with our strength in antibody drug conjugates," said Steve Davidsen, Ph.D., vice president, oncology drug discovery, AbbVie.
04/20/16 10:35 AMBroker Roundup For CytomX Therapeutics, Inc. (NASDAQ:CTMX) - Share Trading News - Broker Roundup For CytomX Therapeutics, Inc. (NASDAQ:CTMX)Share Trading News11/02/2015 – Cowen began new coverage on CytomX Therapeutics, Inc. giving the company a “outperform” rating. The share price of CytomX Therapeutics, Inc. (NASDAQ:CTMX) was down -0.52% during the last trading session, with a day high of 13.60.and more »
04/18/16 10:39 AMCytomX Therapeutics Inc (NASDAQ:CTMX) Analyst Rating Review - Clinton Financial - CytomX Therapeutics Inc (NASDAQ:CTMX) Analyst Rating ReviewClinton FinancialCovering analysts typically give Buy, Sell and Hold recommendations along with guidance and company earnings projections. Currently, there are 3 analysts that have provided ratings for CytomX Therapeutics Inc (NASDAQ:CTMX). 4 have rated the stock a ...and more »
04/16/16 10:11 AMCytomx Therapeutics Incorporated (NASDAQ:CTMX) Sellers Covered 3.22% of Their Shorts - Clinton Financial - Cytomx Therapeutics Incorporated (NASDAQ:CTMX) Sellers Covered 3.22% of Their ShortsClinton FinancialThe short interest to Cytomx Therapeutics Incorporated's float is 5.68%. The stock decreased 0.95% or $0.13 on April 15, hitting $13.52. About 51,060 shares traded hands. CytomX Therapeutics Inc (NASDAQ:CTMX) has risen 6.00% since March 17, 2016 ...Broker Roundup For CytomX Therapeutics, Inc. (NASDAQ:CTMX)Share Trading Newsall 2 news articles »
04/15/16 10:43 AMAnalyst Coverage: CytomX Therapeutics, Inc. (NASDAQ:CTMX) - Risers & Fallers - Analyst Coverage: CytomX Therapeutics, Inc. (NASDAQ:CTMX)Risers & FallersRecently stock market analysts have updated their consensus ratings on shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX). The latest broker reports which are currently outstanding on Friday 15th of April state 0 analysts have a rating of “strong buy”, ...
04/14/16 10:31 AMCytomX Therapeutics Inc (NASDAQ:CTMX): Quick Look at Earnings - News Tribune - CytomX Therapeutics Inc (NASDAQ:CTMX): Quick Look at EarningsNews TribuneWhen CytomX Therapeutics Inc (NASDAQ:CTMX) issues their next quarterly report on or near 2016-06-06, Wall Street analysts are predicting they will report earnings per share of $-0.25. This consensus EPS number is provided by Zacks Research, which ...and more »
04/14/16 10:31 AMEarnings Watch on CytomX Therapeutics Inc (NASDAQ:CTMX) - RiversideGazette.com - Earnings Watch on CytomX Therapeutics Inc (NASDAQ:CTMX)RiversideGazette.comCytomX Therapeutics Inc (NASDAQ:CTMX) has a consensus earnings per share estimate for the current quarter of $-0.25 based on compiled analyst projections. The company is next expected to release earnings on or around 2016-06-06 for the period ...and more »
04/13/16 10:31 AMView on Ratings CytomX Therapeutics Inc (NASDAQ:CTMX) - Business Standard Tribune - View on Ratings CytomX Therapeutics Inc (NASDAQ:CTMX)Business Standard TribuneUsing a scale from 1 to 5, CytomX Therapeutics Inc (NASDAQ:CTMX) has a rating of 1 on the stock. A score of 1 or 2 indicates a Buy rating, and a score of 4 or 5 indicates a Sell rating. A 3 would indicate a Hold. This consensus number is made up of ...CytomX Therapeutics, Inc. (NASDAQ:CTMX) Updated Analyst CoverageRisers & Fallersall 2 news articles »
04/12/16 10:13 AMHow Analysts Feel About CytomX Therapeutics Inc (NASDAQ:CTMX)? - Clinton Financial - How Analysts Feel About CytomX Therapeutics Inc (NASDAQ:CTMX)?Clinton FinancialOut of 3 analysts covering CytomX Therapeutics (NASDAQ:CTMX), 4 rate it “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. CytomX Therapeutics was the topic in 3 analyst reports since November 2, 2015 according to StockzIntelligence Inc.Cytomx Therapeutics Incorporated (NASDAQ:CTMX) Short Interest Increased By 19.76%Franklin IndependentReviewing Share Performance for : CytomX Therapeutics, Inc. (NASDAQ:CTMX)WallStreet.orgAnalysts Expect CytomX Therapeutics Inc (NASDAQ:CTMX) to Announce ($0.25) Earnings Per ShareMas Market NewsRisers & Fallersall 5 news articles »
04/11/16 10:47 AMCytomX Therapeutics Inc (NASDAQ:CTMX) Analyst Recommendation Outlook - Clinton Financial - CytomX Therapeutics Inc (NASDAQ:CTMX) Analyst Recommendation OutlookClinton FinancialCovering analysts usually give Buy, Sell and Hold recommendations along with guidance and company earnings estimates. There are 3 analysts providing ratings for CytomX Therapeutics Inc (NASDAQ:CTMX). 4 have given the stock a “Strong Buy”, 0 rate it ...and more »
04/09/16 09:56 AMNew Analyst Ratings On CytomX Therapeutics, Inc. (NASDAQ:CTMX) - Risers & Fallers - New Analyst Ratings On CytomX Therapeutics, Inc. (NASDAQ:CTMX)Risers & FallersRecently stock market analysts have updated their consensus ratings on shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX). The latest broker reports which are currently outstanding on Friday 8th of April state 3 analysts have a rating of “strong buy”, ...Zacks: CytomX Therapeutics Inc (NASDAQ:CTMX) Given Consensus Rating of "Strong Buy" by BrokeragesWeb Breaking Newsall 2 news articles »
04/08/16 10:27 AMRedmile Group adds CytomX Therapeutics Inc (CTMX) to its portfolio - Everything HUDSON - Redmile Group adds CytomX Therapeutics Inc (CTMX) to its portfolioEverything HUDSONCytomX Therapeutics Inc (CTMX) : Redmile Group added new position in CytomX Therapeutics Inc during the Fourth Quarter. The investment management firm now holds 738,356 shares of CytomX Therapeutics Inc which is valued at $9.2 Million according ...
04/06/16 10:14 AMAnalyst Ratings Check CytomX Therapeutics Inc (NASDAQ:CTMX) - Business Standard Tribune - Analyst Ratings Check CytomX Therapeutics Inc (NASDAQ:CTMX)Business Standard TribuneCovering sell-side analysts have an average rating of 1 on shares of CytomX Therapeutics Inc (NASDAQ:CTMX). This Zacks Research number is compiled from analysts that they have taken into consideration. This consensus rating lands on a 1 to 5 scale.and more »
04/06/16 10:14 AMBroker Changes For CytomX Therapeutics, Inc. (NASDAQ:CTMX) - Risers & Fallers - Broker Changes For CytomX Therapeutics, Inc. (NASDAQ:CTMX)Risers & FallersRecently stock market analysts have updated their consensus ratings on shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX). The latest broker reports which are currently outstanding on Wednesday 6th of April state 3 analysts have a rating of “strong buy ...
04/06/16 10:14 AMAnalysts Predict 20% Gains Ahead For The Holdings of EQWS - ... notable upside to their analyst target prices are Xactly Corp (XTLY), Applied Optoelectronics Inc (AAOI), and CytomX Therapeutics Inc (CTMX). Although XTLY has traded at a recent price of $6.94/share, the average analyst target is 68.10% higher at $11 ...
04/05/16 09:49 AMShould Investors Buy CytomX Therapeutics Inc (NASDAQ:CTMX)? - Clinton Financial - Should Investors Buy CytomX Therapeutics Inc (NASDAQ:CTMX)?Clinton FinancialOut of the 3 analysts covering shares of CytomX Therapeutics Inc (NASDAQ:CTMX), 4 rate it a “Strong Buy”, 0 rate it a “Buy”, 0 are advising to Hold the shares and 0 are saying “Sell”. Each recommendation can be mapped to an integer using a 1 to 5 scale.and more »
About CytomX Therapeutics

CytomX Therapeutics logoCytomX Therapeutics, Inc. is an oncology-focused biopharmaceutical company. The Company is engaged in the development of a class of antibody therapeutics based on its Probody technology platform. It uses its platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against a range of targets. A Probody therapeutic consists of three components produced as a single protein by standard antibody production methodology: an active anti-cancer antibody, a mask for the antibody and a protease-cleavable linker. Its Probody product candidate, CX-072, is directed against programmed death-ligand 1 (PD-L1). CX-072 is based on a monoclonal antibody targeting PD-L1. Its product candidate, CX-2009, is directed against the target CD-166. It is developing a programmed cell death protein 1 (PD-1) Probody therapeutic as an additional approach to block the PD-L1/PD-1 pathway. It is also conducting Integrin alpha-3 PDC program.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: CTMX
  • CUSIP:
Key Metrics:
  • Previous Close: $9.83
  • 50 Day Moving Average: $10.28
  • 200 Day Moving Average: $13.68
  • P/E Ratio: N/A
  • P/E Growth: -0.54
  • Market Cap: $354.74M
  • Current Quarter EPS Consensus Estimate: $-1.40 EPS
Additional Links:
CytomX Therapeutics (NASDAQ:CTMX) Chart for Sunday, June, 26, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha